Comparative Pharmacology
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus HYDRO RX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CANDESARTAN CILEXETIL HYDROCHLOROTHIAZIDE versus HYDRO RX.
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE vs HYDRO-RX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan cilexetil is a prodrug that is hydrolyzed to candesartan, an angiotensin II receptor blocker (ARB) that selectively antagonizes the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption, leading to increased diuresis, decreased plasma volume, and vasodilation. It also reduces peripheral vascular resistance.
Initial dose: 1 tablet (candesartan cilexetil 16 mg / hydrochlorothiazide 12.5 mg) orally once daily; titrate based on response to maximum dose of 32 mg/25 mg once daily.
Initial: 25 mg orally once daily; may increase to 50 mg once daily after 2 weeks based on response. Maximum: 50 mg daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal); Hydrochlorothiazide: 6–15 hours (terminal). Both support once-daily dosing.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; extended to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Candesartan: 33% renal, 67% biliary/fecal. Hydrochlorothiazide: ≥95% renal (unchanged).
Renal excretion of unchanged drug accounts for 60% of elimination; biliary/fecal excretion accounts for 30%; 10% metabolized.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic